Table 2.
Bivariate and multivariate analysis for the primary outcome of the 30 day attributable mortality based on investigators’ assessment
| Relative risk (95% CI) |
||
|---|---|---|
| Characteristic | bivariate analysis | multivariate analysisa |
| MRSA | 1.89 (1.40–2.56) | 1.94 (1.38–2.73) |
| Age, years | 1.03 (1.01–1.04) | 1.02 (1.01–1.03) |
| Male gender | 0.87 (0.67–1.13) | |
| Charlson comorbidity score | 1.14 (1.07–1.22) | 1.10 (1.03–1.19) |
| Pittsburgh bacteraemia score | 1.20 (1.16–1.25) | |
| Source of secondary bacteraemia | 1.28 (0.78–2.04) | |
| Complicated bacteraemia | 1.97 (1.18–3.28) | 1.62 (1.13–2.32) |
| Place of acquisition | ||
| community | (ref)b | (ref)b |
| healthcare associated | 0.63 (0.38–1.04) | 0.58 (0.40–0.83) |
| hospital acquired | 0.69 (0.50–0.92) | 0.64 (0.48–0.86) |
| Comorbidities | ||
| peripheral vascular disease | 1.11 (0.72–1.72) | |
| neurologic disease | 1.64 (0.97–2.77) | |
| surgery | 0.78 (0.56–1.09) | |
| immunosuppressive therapy | 1.26 (0.83–1.91) | |
| Previous MRSA infection | 1.29 (0.63–2.64) | |
| Previous hospitalization | 1.20 (0.85–1.71) | |
| Previous antimicrobial therapy | 1.52 (1.06–2.18) | |
| Clinical information within 48 h before blood sampling | ||
| mechanical ventilation | 1.55 (1.04–2.31) | |
| CVC in place | 0.98 (0.70–1.38) | |
| surgical procedure | 1.05 (0.50–2.22) | |
| Severity of sepsis | ||
| sepsis | (refb) | (refb) |
| multi-organ failure | 3.42 (1.57–7.45) | 2.09 (0.88–4.94) |
| severe sepsis | 2.26 (1.57–2.25) | 1.6 (1.19–2.22) |
| septic shock | 5.46 (3.67–8.14) | 3.60 (2.77–4.69) |
a
Adjusted for clustering on hospital and other significant variables identified in the bivariate analysis.
b
ref, indicates reference for comparison.